Extracellular matrix and cardiac remodelling

Archives des Maladies du Coeur et des Vaisseaux

Volumn 95, Issue 12, 2002, Pages 1226-1229

  Bendall, J K ^a   Heymes, C ^a   Ratajczak, P ^a   Samuel, J L ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 5; COLLAGEN TYPE 6; FIBRONECTIN; INTEGRIN; LAMININ; METALLOPROTEINASE; TENASCIN;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN;

EID: 0036947877     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chen J, Chien KR. Complexity in simplicity: monogenic disorders and complex cardiomyopathies. J Clin Invest 1999; 103: 1483-5.
2. Silvestre JS, Heymes C, Oubenaissa A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-701.
3. Robert V, Heymes C, Silvestre JS et al. Angiatensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-6.
4. Swynghedauw B, Besse S, Assayag P et al. Molecular and cellular biology of the senescent hypertrophied and failing heart. Am J Cardiol 1995; 76: 2D-7D.
5. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998; 4: 69-75.
6. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30.
7. Schwarzbauer JE. Fibronectin: from gene to protein. Curr Opin Cell Biol 1991; 3: 786-91.
8. George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997; 90: 3073-81.
9. Farhadian F, Contard F, Sabri A, Samuel JL, Rappaport L. Fibronectin and basement membrane in cardiovascular or organogenesis and disease pathogenesis. Cardiovasc Res 1996; 35: 433-42.
10. Samuel JL, Barrieux A, Dufour S et al. Accumulation of fetal fibronectin mRNAs during the development of rat cardiac hypertrophy induced by pressure overload. J Clin Invest 1991; 88: 1737-46.
11. Ulrich MM, Janssen AM, Daemen MJ, et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardial 1997; 29: 2533-43.
12. Oliviero P, Chassagne C, Salichon N et al. Expression of laminin alpha2 chain during normal and pathological growth of myocardium in rat and human. Cardiovasc Res 2000; 46: 346-55.
13. Heling A, Zimmermann R, Kostin S et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 2000; 86: 846-53.
14. Tamura K, Chen YE, Chen Q et al. Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. Mol Cell Biochem 2000; 212: 203-9.
15. Chassagne C, Adamy C, Ratajczak P et al. Angiotensin II AT(2) receptor inhibits smooth muscle cell migration via fibronectin cell production and binding. Am J Physiol Cell Physiol 2002; 282: C654-C664.
16. Grimm D, Kramer EP, Backer Wet al. Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. J Hypertens 1998; 16: 1345-55.
17. Imanaka-Yoshida K, Hiroe M, Nishikawa T et al. Tenascin-C modulates adhesion of cardiomyacytes to extracellular matrix during tissue remodelling after myocardial infarction. Lab Invest 2001; 81: 1015-24.
18. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000; 105: 21-34.
19. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
20. Robert V, Besse S, Sabri A et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 1997; 76: 729-38.
21. Spinale FG, Coker ML, Krombach SR et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 1999; 85: 364-76.
22. Heymans S, Luttun A, Nuyens D et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med 1999; 5: 1135-42.
23. Ducharme A, Frantz S, Aikawa M et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
24. Ross RS, Borg TK. Integrins and the myocardium. Circ Res 2001; 88: 1112-9.
25. Yamada KM, Miyamoto S. Integrin transmembrane signalling and cytoskeletal control. Curr Opin Cell Biol 1995; 7: 681-9.
26. Hynes RO. Integrins: versatility, modulation and signalling in cell adhesion. Cell 1992; 69: 11-25.
27. Belkin AM, Retta F, Pletjushkina OY et al. Muscle b1-D integrin reinforces the cytoskeleton-matrix link: modulation of integrin adhesive function by alternative splicing. J Cell Biol 1997; 139: 1583-95.
28. Baudain C, Gaumans MJ, Mummery C, Sonnenberg A. Knockout and knockin of the beta1 exon D define distinct roles for integrin splice variants in heart function and embryonic development. Genes Dev 1998; 12: 1202-16.
29. Keller RS, Shai SY, Babbitt CJ et al. Disruption of integrin function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance. Am J Pathol 2001; 158: 1079-90.
30. Shai SY, Harpf AE, Babbitt CJ et al. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res 2002; 90: 458-64.